Puri Ajay, Byregowda Suman, Gulia Ashish, Crasto Saniya, Chinaswamy Girish
Tata Memorial Centre, HBNI, Mumbai, India.
J Surg Oncol. 2018 Feb;117(2):299-306. doi: 10.1002/jso.24809. Epub 2017 Aug 22.
To review outcomes of 853 patients of primary high grade osteosarcoma operated with curative intent between January 2006 to December 2013.
All patients underwent appropriate surgical resection after preoperative chemotherapy (non methotrexate based). Excised specimen was analyzed for margins and response to chemotherapy. We analysed various factors (sex, age, size, site, type of surgery, pathologic fractures, margin status, and chemotherapy induced necrosis) for their impact on outcomes.
Five year overall survival (OS) for entire cohort was 49% and event free survival (EFS) was 42%. Seventy hundred thirty-eight non metastatic patients had OS of 53% and EFS of 47% at 5 years. The 3 year OS and EFS of the metastatic patients was 22% and 9%, respectively. Analysis of 738 non metastatic patients demonstrated that chemotherapy induced necrosis, size of tumor (< / >8 cms), type of surgery (limb salvage vs amputation) significantly affected overall survival. Local recurrence was 9%. Site of tumor (long bone vs pelvis), type of surgery and chemotherapy induced necrosis influenced local recurrence.
Our patients appeared to have poorer survival compared to most Western data, possibly attributable to large tumors. In contrast to existing data, males (71%) were predominantly affected and only patients with 100% necrosis qualified as good responders regarding OS.
回顾2006年1月至2013年12月间853例接受根治性手术的原发性高级别骨肉瘤患者的治疗结果。
所有患者在术前化疗(非基于甲氨蝶呤)后接受了适当的手术切除。对切除标本进行切缘分析及化疗反应分析。我们分析了各种因素(性别、年龄、大小、部位、手术类型、病理性骨折、切缘状态和化疗诱导的坏死)对治疗结果的影响。
整个队列的5年总生存率(OS)为49%,无事件生存率(EFS)为42%。738例非转移性患者的5年OS为53%,EFS为47%。转移性患者的3年OS和EFS分别为22%和9%。对738例非转移性患者的分析表明,化疗诱导的坏死、肿瘤大小(< / >8厘米)、手术类型(保肢与截肢)显著影响总生存率。局部复发率为9%。肿瘤部位(长骨与骨盆)手术类型和化疗诱导的坏死影响局部复发。
与大多数西方数据相比,我们的患者生存率似乎较低,可能归因于肿瘤较大。与现有数据相反,男性(71%)受影响为主,只有坏死率达100%的患者在总生存率方面符合良好反应者标准。